Neboglamine
This note is educational and is not personal medical advice. Effects vary by baseline status, dose, product quality, medications, sleep debt, diet, and health conditions.
Summary / What it does
Neboglamine is a synthetic compound that modulates the glycine co-agonist site of NMDA receptors. By influencing NMDA receptor activation conditions, it may support synaptic plasticity, memory consolidation, and cognitive function in impaired states. Human evidence is essentially absent.
Useful cross-links: Glutamate, AMPA, NMDA Modulation, Neurotransmitter Balance. Its effects are best evaluated through the Acute & Instant Effects pattern rather than as a single isolated effect.
How it works in the brain (detailed scientific mechanisms)
NMDA receptors require simultaneous binding of glutamate and a co-agonist (glycine or D-serine) at the glycine-B site for activation. The glycine-B site is not always saturated under physiological conditions, meaning modulation at this site can regulate NMDA receptor sensitivity without completely opening or blocking the channel. Neboglamine acts at or near this co-agonist site, influencing the frequency and quality of NMDA receptor activation.
NMDA receptor activation is the molecular trigger for LTP — the synaptic strengthening mechanism underlying memory consolidation. In states of cognitive impairment or NMDA hypofunction (which has been implicated in both aging-related memory decline and conditions like schizophrenia), enhancing NMDA-receptor co-agonism at the glycine site could partially restore LTP capacity. This is the same broad strategy as glycine and D-serine supplementation, but with a more targeted synthetic approach. The risk landscape includes potential for NMDA overactivation and excitotoxicity if the modulatory dose-response is not well-controlled.
Related mechanism notes: Glutamate, AMPA, NMDA Modulation, Neurotransmitter Balance.
Different variations/forms
Research compound only. No standardized consumer form.
Time to action / onset
Not established in humans.
Half-life
Not publicly established.
Dosage
No established human dose. Not for self-administration.
Positive effects
Theoretical: improved memory encoding, LTP support, and cognitive rescue in NMDA hypofunction states.
Reported Effects
No established human experience profile exists.
Side effects / contraindications
Unknown in humans. The glycine-B site modulation approach theoretically avoids direct excitotoxic risk better than direct NMDA agonists, but NMDA overactivation at higher exposures remains a concern. Interactions with antipsychotics and other glutamate-active drugs are unpredictable.
Where it is found in food or nature (natural sources)
Neboglamine is fully synthetic with no natural food sources. It is structurally distinct from endogenous glycine.
Protocol
No protocol can be responsibly recommended. Neboglamine has no established human dosing or safety profile. Do not self-administer.
Key Research
- Urwyler et al. (1996): Established neboglamine’s modulation at the NMDA glycine-B site in membrane receptor binding assays and electrophysiology.
- Collingridge & Bliss (1995): Foundational review linking glycine-B site modulation to LTP mechanisms — the mechanistic context for neboglamine-class compounds.
- Parsons et al. (1997): Explored glycine-site partial agonists as a therapeutic strategy for cognitive impairment in schizophrenia and Alzheimer’s disease.
Forms & Sourcing
Not available as a consumer supplement. Research synthesis only.
Other notes
Neboglamine occupies a similar niche to ACD-856 and BPN-14770 — novel mechanistic approaches to NMDA-based memory enhancement. Its glycine-site mechanism is related to why dietary Glycine and Magnesium (NMDA-modulating) are relevant in mainstream nootropic use.
Related notes: ACD-856, BPN-14770, Magnesium, Glycine, Glutamate, AMPA, NMDA Modulation